High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients

被引:65
作者
Kasuga, A
Maruyama, T
Nakamoto, S
Ozawa, Y
Suzuki, Y
Saruta, T
机构
[1] Tokyo Denryoku Hosp, Dept Internal Med, Shinjuku Ku, Tokyo 1600016, Japan
[2] Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan
[3] Social Insurance Saitama Chuo Hosp, Dept Internal Med, Urawa, Saitama, Japan
[4] Natl Okura Hosp, Dept Internal Med, Tokyo, Japan
关键词
GAD antibody; HLA class II; IAA; IA-2; antibody; type; 1; diabetes;
D O I
10.1006/jaut.1998.0261
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibodies against glutamic acid decarboxylase (GADA) is known to be a good predictive marker for insulin-dependency among adult diabetic patients. However, since clot all of the GADA-positive patients will develop insulin requirement, we investigated whether other markers, that is, antibodies against IA-2 (IA-2A), insulin autoantibodies (IAA) and HLA class II type, would affect its predictive value for insulin requirement. Adult diabetic patients in the non-insulin-requiring stage were screened for GADA and registered in the study if positive. At the end of the follow-up period, 15 of the 43 GADA-positive patients required insulin. Among GADA-positive patients, the GADA titers of the insulin-requiring patients were significantly higher (199 U vs. 5.8 U, P<0.001) and high-titer GADA was more frequently detected among insulin-requiring patients (80% vs. 11%, P<0.0001). IAA was more frequently detected in insulin-requiring patients (40% vs. 0%, P<0.001), and IA-2A was detected only among insulin-requiring patients. Combinations of these three antibodies (GADA with either IAA or IA-2A) had 100% positive predictive value. in conclusion, the GADA test is a good screening test for predicting insulin requirement in adult diabetic patients and both the IAA and IA-2A tests are useful second line tests. (C) 1999 Academic Press.
引用
收藏
页码:131 / 135
页数:5
相关论文
共 23 条
[1]   RISK FOR DEVELOPING TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS AND THE PRESENCE OF ISLET 64K ANTIBODIES [J].
BARMEIER, H ;
MCCULLOCH, DK ;
NEIFING, JL ;
WARNOCK, G ;
RAJOTTE, RV ;
PALMER, JP ;
LERNMARK, A .
DIABETOLOGIA, 1991, 34 (10) :727-733
[2]   Prediction of IDDM in the general population - Strategies based on combinations of autoantibody markers [J].
Bingley, PJ ;
Bonifacio, E ;
Williams, AJK ;
Genovese, S ;
Bottazzo, GF ;
Gale, EAM .
DIABETES, 1997, 46 (11) :1701-1710
[3]  
BONIFACIO E, 1995, J IMMUNOL, V155, P5419
[4]   INSULIN AUTOANTIBODIES IN THE PREDIABETIC PERIOD - CORRELATION WITH ISLET CELL ANTIBODIES AND DEVELOPMENT OF DIABETES [J].
DEAN, BM ;
BECKER, F ;
MCNALLY, JM ;
TARN, AC ;
SCHWARTZ, G ;
GALE, EAM ;
BOTTAZZO, GF .
DIABETOLOGIA, 1986, 29 (05) :339-342
[5]  
EISENBARTH GS, 1994, JOSLINS DIABETES MEL, P216
[6]   RADIOIMMUNOASSAYS FOR GLUTAMIC-ACID DECARBOXYLASE (GAD65) AND GAD65 AUTOANTIBODIES USING S-35 OR H-3 RECOMBINANT HUMAN LIGANDS [J].
FALORNI, A ;
ORTQVIST, E ;
PERSSON, B ;
LERNMARK, A .
JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 186 (01) :89-99
[7]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[8]   ICA512 AUTOANTIBODY RADIOASSAY [J].
GIANANI, R ;
RABIN, DU ;
VERGE, CF ;
YU, LP ;
BABU, SR ;
PIETROPAOLO, M ;
EISENBARTH, GS .
DIABETES, 1995, 44 (11) :1340-1344
[9]  
Kasuga A, 1996, ACTA DIABETOL, V33, P108
[10]   Autoantibody against IA-2 improves the test sensitivity for insulin-dependent diabetes mellitus in Japanese patients of child onset [J].
Kasuga, A ;
Ozawa, Y ;
Maruyama, T ;
Ishihara, T ;
Amemiya, S ;
Saruta, T .
ENDOCRINE JOURNAL, 1997, 44 (04) :485-491